These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 15778420

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans.
    Fuse E, Tanii H, Takai K, Asanome K, Kurata N, Kobayashi H, Kuwabara T, Kobayashi S, Sugiyama Y.
    Cancer Res; 1999 Mar 01; 59(5):1054-60. PubMed ID: 10070963
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01.
    Kurata N, Kuwabara T, Tanii H, Fuse E, Akiyama T, Akinaga S, Kobayashi H, Yamaguchi K, Kobayashi S.
    Cancer Chemother Pharmacol; 1999 Mar 01; 44(1):12-8. PubMed ID: 10367744
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Controlled release of a protein kinase inhibitor UCN-01 from liposomes influenced by the particle size.
    Yamauchi M, Kusano H, Saito E, Abe M, Tsutsumi K, Uosaki Y, Nakakura M, Kato Y, Aoki N.
    Int J Pharm; 2008 Mar 03; 351(1-2):250-8. PubMed ID: 17904317
    [Abstract] [Full Text] [Related]

  • 8. On the observed large interspecies overprediction of human clearance ("vertical allometry") of UCN-01: further support for a proposed model based on plasma protein binding.
    Tang H, Mayersohn M.
    J Clin Pharmacol; 2006 Apr 03; 46(4):398-400. PubMed ID: 16554445
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein.
    Bhonde MR, Hanski ML, Magrini R, Moorthy D, Müller A, Sausville EA, Kohno K, Wiegand P, Daniel PT, Zeitz M, Hanski C.
    Oncogene; 2005 Jan 06; 24(1):148-56. PubMed ID: 15467762
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V, Schuck EL, Pelletier RD, Farah N, Condon KB, Ye M, Rowbottom C, King BM, Zhang ZY, Saxton PL, Wong YN.
    Cancer Chemother Pharmacol; 2012 Jan 06; 69(1):229-37. PubMed ID: 21698359
    [Abstract] [Full Text] [Related]

  • 16. The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogs.
    Kurata N, Imabeppu S, Nitoh M, Kobayashi H, Kuwabara T, Kobayashi S.
    J Pharm Pharmacol; 2000 Nov 06; 52(11):1327-35. PubMed ID: 11186240
    [Abstract] [Full Text] [Related]

  • 17. Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human alpha1-acid glycoprotein.
    Fuse E, Hashimoto A, Sato N, Tanii H, Kuwabara T, Kobayashi S, Sugiyama Y.
    Pharm Res; 2000 May 06; 17(5):553-64. PubMed ID: 10888307
    [Abstract] [Full Text] [Related]

  • 18. Implications of p53 in growth arrest and apoptosis on combined treatment of human Mammary epithelial cells with topotecan and UCN-01.
    Redkar A, Mixter P, Daoud SS.
    J Exp Ther Oncol; 2004 Oct 06; 4(3):213-22. PubMed ID: 15724841
    [Abstract] [Full Text] [Related]

  • 19. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
    Li M, Wang H, Hill DL, Stinson S, Veley K, Grossi I, Peggins J, Covey JM, Zhang R.
    Cancer Chemother Pharmacol; 2006 May 06; 57(5):607-14. PubMed ID: 16331493
    [Abstract] [Full Text] [Related]

  • 20. In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
    Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK.
    Clin Cancer Res; 2004 Aug 01; 10(15):5242-52. PubMed ID: 15297428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.